Literature DB >> 26546024

CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review.

G Colloca1, A Venturino2, I Governato3.   

Abstract

Various kinetic parameters, based on a minimum of two time points, have been built with CA125 determinations. The aim of this study is to review studies about the clinical application of CA125-related tumor cell kinetics variables in patients with advanced ovarian cancer (AOC) receiving chemotherapy. A literature search for studies about CA125-related variables in patients with AOC was undertaken on three databases, by predefined search criteria, and a selection of studies was performed. Sixty-two studies were selected. CA125-related variables were summarized in three groups: response-related, time-to-event, and other CA125-related tumor cell kinetics variables. Even though CA125 changes and half-life after chemotherapy were the most studied, other variables and two models have been well defined, and often showed an interesting power to predict survival. These kinetics variables are related to the CA125 regression curve, pre- and post-chemotherapy kinetics, or are variables inferred from a population model of CA125 kinetics.

Entities:  

Keywords:  CA125; Chemotherapy; Ovarian cancer; Tumor growth kinetics

Mesh:

Substances:

Year:  2015        PMID: 26546024     DOI: 10.1007/s12094-015-1441-5

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  95 in total

Review 1.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

2.  Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.

Authors:  Maurie Markman
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

3.  CA 125 kinetics: a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s.

Authors:  R E Buller; S Vasilev; P J DiSaia
Journal:  Am J Obstet Gynecol       Date:  1996-04       Impact factor: 8.661

4.  Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.

Authors:  G J Rustin; A E Nelstrop; P McClean; M F Brady; W P McGuire; W J Hoskins; H Mitchell; H E Lambert
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

5.  CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer.

Authors:  P Sevelda; M Schemper; J Spona
Journal:  Am J Obstet Gynecol       Date:  1989-11       Impact factor: 8.661

6.  The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma.

Authors:  Naveen S Vasudev; Ioannis Trigonis; David A Cairns; Geoff D Hall; David P Jackson; Timothy Broadhead; John Buxton; Richard Hutson; David Nugent; Timothy J Perren
Journal:  Arch Gynecol Obstet       Date:  2010-08-29       Impact factor: 2.344

7.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

Authors:  E A Eisenhauer; W W ten Bokkel Huinink; K D Swenerton; L Gianni; J Myles; M E van der Burg; I Kerr; J B Vermorken; K Buser; N Colombo
Journal:  J Clin Oncol       Date:  1994-12       Impact factor: 44.544

8.  A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundant.

Authors:  G Frasci; S Conforti; F Zullo; P Mastrantonio; G Comella; P Comella; G Persico; R V Iaffaioli
Journal:  Cancer       Date:  1996-03-15       Impact factor: 6.860

9.  CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer.

Authors:  C Peters-Engl; A Obermair; H Heinzl; P Buxbaum; P Sevelda; M Medl
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

10.  A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer.

Authors:  An Jen Chiang; Jiabin Chen; Yu-Che Chung; Huan-Jung Huang; Wen Shiung Liou; Chung Chang
Journal:  J Gynecol Oncol       Date:  2014-01-08       Impact factor: 4.401

View more
  4 in total

Review 1.  Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer.

Authors:  Giuseppe Colloca; Antonella Venturino
Journal:  Med Oncol       Date:  2017-04-08       Impact factor: 3.064

2.  The Effect of Delayed Chemotherapy on the Decrease of CA125 in Epithelial Ovarian Cancer During Coronavirus Disease Pandemic in 2020.

Authors:  Qiang Yi; Yu Ran; Cong Li
Journal:  Cancer Manag Res       Date:  2021-01-19       Impact factor: 3.989

3.  Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer.

Authors:  Jorge A Alegría-Baños; José C Jiménez-López; Arely Vergara-Castañeda; David F Cantú de León; Alejandro Mohar-Betancourt; Delia Pérez-Montiel; Gisela Sánchez-Domínguez; Mariana García-Villarejo; César Olivares-Pérez; Ángel Hernández-Constantino; Acitlalin González-Santiago; Miguel Clara-Altamirano; Liz Arela-Quispe; Diddier Prada-Ortega
Journal:  J Ovarian Res       Date:  2021-07-19       Impact factor: 4.234

4.  Prognostic molecular biomarkers in endometrial cancer: A review.

Authors:  J Edgardo Hernández; Ailyn González-Montiel; Jesús C Ceb Allos-Villalva; David Cantú; Salim Barquet; Anny Olivares-Mundo; Luis A Herrera; Diddier Prada
Journal:  J Cancer Res Ther (Manch)       Date:  2019-12-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.